Articles Related to tablet
Randomised, 2-Sequence, 4-Period Replicate Cross-Over Bioequivalence Study of A New Riluzole Orodispersible Film Vs. A Reference Tablet in Healthy Volunteers
Purpose: The present bioequivalence study aimed at demonstrating the bioequivalence of a recently developed novel riluzole orodispersible film vs. a reference tablet.
Methods: Healthy male and female volunteers received single oral doses of 50 mg of riluzole, as test and reference formulation, under fasting conditions, in each of 4 subsequent periods separated by wash-out intervals of at least 7 days, according to a 2-treatment, 4-period, replicate randomised cross-over design.
Findings: Riluzole plasma concentrations were almost superimposable. Riluzole attained a similar peak concentration (315.62±124.95 ng/mL with the film and 278.81±123.32 ng/mL with the tablet) at a median tmax of 0.75 h after both treatments. Then, riluzole plasma concentrations showed a superimposable decline from the peak up to 36 h post-dose, with mean half-lives of 10.22±1.66 and 10.22±1.48 h with the film and the tablet. Mean AUC0-t was 1263.40±571.58 h*ng/mL with the film and 1135.98±514.98 h*ng/mL with the tablet. The 90% confidence intervals of Cmax, AUC0-t and AUC0-¥ of riluzole fell within the predefined range 80.00-125.00%. The treatments did not differ significantly either in tmax or t1/2. On average, the test orodispersible film dissolved on the tongue in a median time of about 2.5 min with a range of 0.7-5.7 min. Orodispersible film palatability was good or acceptable for most subjects.
Stability Indicating Method Development and Validation for the Determination of Armodafinil in Pharmaceutical Tablet Dosage Form by RP-HPLC
The present research deals with the development of a stability indicating reverse phase HPLC with PDA detector method
for the determination of Armodafinil Agilent XDB-C18, 150×4.6mm, 5µm or Equivalent column. The present research
deals with the development of a stability indicating reverse phase HPLC with PDA detector method for the determination
of Armodafinil Agilent XDB-C18,
Bioequivalence Study of Donepezil 10 mg Orally Disintegrating Tablets in Healthy Thai Volunteers Under Fasting Conditions
Donepezil is a potent, selective, noncompetitive and reversible inhibitor of acetylcholinesterase, commonly used for the treatment of Alzheimer’s disease. The form of orally disintegrating tablets (ODTs) is a good alternative dosage form for patients who have a difficulty in swallowing conventional tablets or capsules.
Comparative Bioequivalence Studies of Pantoprazole 40 mg Delayed-Release Tablet Formulations in Healthy Thai Volunteers
Pantoprazole is a H+,K+-ATPase enzyme inhibitor for the treatment of acid-related gastrointestinal diseases. The Government Pharmaceutical Organization (GPO), Thailand had developed Pantoprazole GPO® (pantoprazole 40 mg delayed-release tablets) as a generic substitute for the corresponding innovator product, CONTROLOC® 40 mg.
Bioequivalence of Two Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600/200/300 mg Fixed-Dose Combination Tablets in Healthy Thai Male Volunteers under Fasting Conditions
Fixed-dose combination tablet formulation of efavirenz/emtricitabine/tenofovir disoproxil fumarate 600/200/300 mg is an antiretroviral
therapy comprising one non-nucleoside reverse-transcriptase inhibitor and two nucleoside reverse-transcriptase inhibitors to control
human immunodeficiency virus infection.
Bioequivalence Evaluation of Two Clopidogrel Immediate Release Tablet Formulations in Healthy Thai Volunteers Under Fasting Conditions
Clopidogrel is used for acute coronary syndrome and prevention of atherothrombotic events. To improve clinical outcomes, patient
adherence to treatment is necessary. However, continuous use of branded product may cause economic burden to patients and
healthcare system. The Government Pharmaceutical Organization (GPO), Thailand had developed a generic product of clopidogrel to
reduce cost of treatment and improve accessibility to medicines for Thai people.
Bioequivalence between Two Tablets of Levetiracetam in Healthy Subjects under Fasting Condition
Bioavailability of two formulations containing levetiracetam 750 mg film-coated tablets was compared in a fasting bioequivalence study. The study was single dose, randomized, open label, and two-period crossover, with Brazilian healthy subjects, males and nonpregnant females. Blood samples were taken for 36 hours after drug administration and plasmatic concentrations were determined using a validated HPLC-MS/MS method. Confidence intervals (CI90%) for the peak plasma concentration (Cmax) and area under the
concentration-time curve (AUC0-t) were determined by calculating LN-transformed data. The ratios and 90% CI for the geometric mean test/reference were 97.41% (91.45- 103.75%) for Cmax and 99.77% (97.07- 102.54%) for AUC0-t.
Bioequivalence Study of Olanzapine 5 mg Orally Disintegrating Tablet Formulations in Healthy Thai Volunteers under Fasting Conditions
A comparative randomized, single dose, two-way crossover, open label study was carried out to assess bioequivalence and tolerability of test (ZOLAN GPO®) and reference (Zyprexa Zydis®) products of olanzapine 5 mg orally disintegrating tablets for interchange ability in the same quality and safety.
A Bioequivalence Study of Two Formulations of Rosuvastatin
Aim of this study was to compare the bioavailability of two tablet formulations containing Rosuvastatin: Rosuvastatin tablets 40 mg manufactured by MacLeods Pharmaceuticals Ltd. (marketed in Italy with the brand name Exorta®) and CRESTOR® 40 mg tablets marketed by Astra Zeneca.
A Bioequivalence Study of Two Formulations of Levetiracetam
This study was conducted to compare the bioavailability of 1000 mg levetiracetam film-coated tablet, marketed in Italy as Italept®, with Keppra® coated tablet.
Bioequivalence between two extended Release Tablets of Oxycodone Hydrochloride in Healthy Subjects under Fasting and Fed Conditions
Bioavailability of different formulations of oxycodone 20 mg extended release tablets was compared in two bioequivalence studies, one under fasting conditions and the other one after a high-fat breakfast.
Pharmacokinetics of a 1,000 mg Disintegrating Aspirin Tablet Formulation
Migraine is a global disorder and considerably affecting people`s quality of life. Treatments include nonsteroidal anti-inflammatory drugs-containing medicinal products among whom acetylsalicylic acid-containing Aspirin® has been proven effectively to relief migraine headache. Early treatment is recommended for patients with migraine attacks.
Bioequivalence between two Prolonged Release Tablets of Desvenlafaxine Succinate in Healthy Subjects under Fasting and Fed Conditions
Bioavailability in different formulations of desvenlafaxine100 mg prolonged-release tablets was compared in two bioequivalence studies, one under fasting conditions and the other after a standard breakfast. Both studies were a single dose, randomized, open-label, two-period crossover, with Brazilian male and female healthy subjects. Blood samples were taken during 48 h and plasmatic concentrations were determined using a validated UPLC-MS/MS method.
Orally Disintegrating Tablets: A Short Review
This article summarizes the advantages of orally disintegrating tablets (ODTs) as well as critical issues during evaluation of ODTs such as bioequivalence and challenges and limitations of ODTs and finally present and the future of ODTs. ODTs have received everincreasing demand and the field has become a rapidly growing area in the pharmaceutical industry.
Evaluation of Luffa Aegyptica Mill Powder: A Novel Superdisintegrant in Delayed Release Tablets
The current research in the field of drug delivery by which pulsatile release can be achieved has been intensified. The objective of the present study was to evaluate Luffa aegyptica mill powder as a novel superdisintegrant in the development of pulsatile drug delivery system (PDDS).
Editorial Board Members Related to tablet
ALAA EL-DEEN BAKRY YASSIN
Associate Professor
Department of Pharmaceutical Sciences
King Saud bin Abdulaziz University for Health Sciences
Saudi Arabia
Department of Pharmaceutical Sciences
King Saud bin Abdulaziz University for Health Sciences
Saudi Arabia
NORMA RANGEL
Professor Research
Division of Graduate Studies and Research
Institute of Technology Aguascalientes (ITA)
Technological Institute of Aguascalientes (ITA)
Mexico
Division of Graduate Studies and Research
Institute of Technology Aguascalientes (ITA)
Technological Institute of Aguascalientes (ITA)
Mexico
Khalid M. El-Say
Associate professor
Department of Pharmaceutics and Industrial pharmacy
King Abdulaziz University
Saudi Arabia
Department of Pharmaceutics and Industrial pharmacy
King Abdulaziz University
Saudi Arabia
TIMUCIN UGURLU
Associate Professor
Department of Pharmaceutical Technology
Marmara University
Turkey
Department of Pharmaceutical Technology
Marmara University
Turkey
